|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2006-11-7
|
|
pubmed:abstractText |
Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanamine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic Uptake Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Biogenic Amines,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Plasma Membrane Transport...,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Propylamines,
http://linkedlifedata.com/resource/pubmed/chemical/SLC6A4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Plasma Membrane...,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0968-0896
|
|
pubmed:author |
pubmed-author:LeventhalLizaL,
pubmed-author:MahaneyPaige EPE,
pubmed-author:McComasCasey CCC,
pubmed-author:NogleLisa MLM,
pubmed-author:SarkahianAniA,
pubmed-author:SullivanNicole RNR,
pubmed-author:TrybulskiEugene JEJ,
pubmed-author:UvegesAlbert JAJ,
pubmed-author:VuAn TAT,
pubmed-author:WattsWilliam LWL,
pubmed-author:ZhangPuwenP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8455-66
|
|
pubmed:meshHeading |
pubmed-meshheading:16973367-Adrenergic Uptake Inhibitors,
pubmed-meshheading:16973367-Biogenic Amines,
pubmed-meshheading:16973367-Cell Line, Tumor,
pubmed-meshheading:16973367-Choriocarcinoma,
pubmed-meshheading:16973367-Dopamine Plasma Membrane Transport Proteins,
pubmed-meshheading:16973367-Humans,
pubmed-meshheading:16973367-Indoles,
pubmed-meshheading:16973367-Norepinephrine,
pubmed-meshheading:16973367-Placenta,
pubmed-meshheading:16973367-Propylamines,
pubmed-meshheading:16973367-Serotonin,
pubmed-meshheading:16973367-Serotonin Plasma Membrane Transport Proteins,
pubmed-meshheading:16973367-Serotonin Uptake Inhibitors,
pubmed-meshheading:16973367-Structure-Activity Relationship
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines.
|
|
pubmed:affiliation |
Chemical and Screening Sciences, Discovery Medicinal Chemistry, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA. mahanep@wyeth.com
|
|
pubmed:publicationType |
Journal Article
|
